Central proinflammatory cytokines and pain enhancement

NeuroSignals

Volumn 14, Issue 4, 2005, Pages 166-174

  Wieseler Frank, Julie ^a   Maier, Steven F ^a   Watkins, Linda R ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Allodynia; Astrocyte; Hyperalgesia; Interleukin 1; Interleukin 6; Microglia; Pain facilitation; Proinflammatory cytokines; Sickness behavior; Tumor necrosis factor alpha

Indexed keywords

CYTOKINE; INTERLEUKIN 10;

ASTROCYTE; CENTRAL NERVOUS SYSTEM; CYTOKINE RELEASE; EVOLUTION; GENE THERAPY; GLIA CELL; MICROGLIA; PAIN; PATHOLOGY; PROTEIN FUNCTION; REVIEW; SPINAL CORD; SURVIVAL; SYNTHESIS;

ANIMALS; CENTRAL NERVOUS SYSTEM; CYTOKINES; HUMANS; INFLAMMATION; NEUROGLIA; PAIN;

EID: 26244444488     PISSN: 1424862X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000087655     Document Type: Review

References (89)

1. Watkins LR, Maier SF: Beyond neurons: evidence that immune and glial cells contribute to pathological pain states. Physiol Rev 2002;82:981-1011.
2. Willis WDJ (ed): Hyperalgesia and Allodynia. New York, Raven Press, 1992.
3. Barres BA: New roles for glia. J Neurosci 1991;11:3685-3694.
4. Barres BA, Barde Y: Neuronal and glial cell biology. Curr Opin Neurobiol 2000;10:642-648.
5. Maier, SF, Watkins LR: Cytokines for psychologists: implications of bidirectional immune-to-brain communication for understanding behavior, mood, and cognition. Psychol Rev 1998;105:83-107.
6. Hart BL: Behavior of sick animals. Vet Clin N Am Food Anim Pract 1987;3:383-391.
7. Hart BL: Biological basis of the behavior of sick animals. Neurosci Biobehav Rev 1988;12:123-137.
8. Kent S, Bluthe RM, Kelley KW, Dantzer R: Sickness behavior as a new target for drug development. Trends Pharmacol Sci 1992;13:24-28.
9. Maier SF, Wiertelak EP, Watkins LR: Endogenous pain facilitatory systems: anti-analgesia and hyperalgesia. Am Pain Soc J 1992;1:191-198.
10. Watkins LR, Maier SF: The pain of being sick: implications of immune-to-brain communication for understanding pain. Annu Rev Psychol 2000;51:29-57.
11. McCarthy DO, Kluger MJ, Vander AJ: Effect of centrally administered interleukin-1 and endotoxin on food intake of fasted rats. Physiol Behav 1986;36:745-749.
12. Rothwell NJ: Central effects of TNF alpha on thermogenesis and fever in the rat. Biosci Rep 1988;8:345-352.
13. Watkins LR, Martin D, Ulrich P, Tracey KJ, Maier SF: Evidence for the involvement of spinal cord glia in subcutaneous formalin induced hyperalgesia in the rat. Pain 1997;71:225-235.
14. Watkins LR, Goehler LE, Relton JK, Tartaglia N, Silbert L, Martin D, Maier SF: Blockade of interleukin-1 induced hyperthermia by subdiaphragmatic vagotomy: evidence for vagal mediation of immune-brain communication. Neurosci Lett 1995;183:27-31.
15. Maier SF, Wiertelak EP, Martin D, Watkins LR: Interleukin-1 mediates the behavioral hyperalgesia produced by lithium chloride and endotoxin. Brain Res 1993;623:321-324.
16. Watkins LR, Maier SF, Goehler LE: Immune activation: the role of pro-inflammatory cytokines in inflammation, illness responses and pathological pain states. Pain 1995;63:289-302.
17. Watkins LR, Wiertelak EP, Goehler LE, Mooney-Heiberger K, Martinez J, Furness L, Smith KP, Maier SF: Neurocircuitry of illness-induced hyperalgesia. Brain Res 1994;639:283-299.
18. Wiertelak EP, Roemer B, Maier SF, Watkins LR: Comparison of the effects of nucleus tractus solitarius and ventral medial medulla lesions on illness-induced and subcutaneous formalin-induced hyperalgesias. Brain Res 1997;748:143-150.
19. Graeber MB, Streit WJ, Kreutzberg GW: Axotomy of the rat facial nerve leads to increased CR3 complement receptor expression by activated microglial cells. J Neurosci Res 1988;21:18-24.
20. Hajos F, Csillik B, Knyihar-Csillik E: Alterations in glial fibrillary acidic protein immunoreactivity in the upper dorsal horn of the rat spinal cord in the course of transganglionic degenerative atrophy and regenerative proliferation. Neurosci Lett 1990;117:8-13.
21. Hall LL, Borke RC, Anders JJ: Transection or electrical stimulation of the hypoglossal nerve increases glial fibrillary acidic protein immunoreactivity in the hypoglossal nucleus. Brain Res 1989;490:157-161.
22. Sjostrand J: Neuroglial proliferation in the hypoglossal nucleus after nerve injury. Exp Neurol 1971;30:178-189.
23. Tetzlaff W, Graeber MB, Bisby MA, Kreutzberg GW: Increased glial fibrillary acidic protein synthesis in astrocytes during retrograde reaction of the rat facial nucleus. Glia 1988;1:90-95.
24. Garrison CJ, Dougherty PM, Kajander KC, Carlton SM: Staining of glial fibrillary acidic protein (GFAP) in lumbar spinal cord increases following a sciatic nerve constriction injury. Brain Res 1991;565:1-7.
25. Garrison CJ, Dougherty PM, Carlton SM: GFAP expression in lumbar spinal cord of naive and neuropathic rats treated with MK-801. Exp Neurol 1994;129:237-243.
26. Schousboe A, Westergaard N: Transport of neuroactive amino acids in astrocytes; in Kettenmann H, Ransom BR (eds): Neuroglia. New York, Oxford University Press, 1995, pp 246-258.
27. Ransom BR: Glial modulation of neural excitability mediated by extracellular pH: a hypothesis. Prog Brain Res 1992;94:37-46.
28. Kreutzberg GW: Microglia: a sensor for pathological events in the CNS. Trends Neurosci 1996;19:312-318.
29. Ridet JL, Malhotra SK, Privat A, Gage FH: Reactive astrocytes: cellular and molecular cues to biological function. Trends Neurosci 1997;20:570-577.
30. Marriott DR, Wilkin GP, Wood JN: Substance P-induced release of prostaglandins from astrocytes: regional specialisation and correlation with phosphoinositol metabolism. J Neurochem 1991;56:259-265.
31. Verge G, Milligan ED, Twining C, Maier SF, Watkins LR, Foster AC, Naeve GS: Mapping fractalkine and its receptor (CX3CR1) in a rat model of sciatic inflammatory neuropathy (SIN). Proc Soc Neurosci 2002;28.
32. Ochalski, PA, Frankenstein UN, Hertzberg EL, Nagy JI: Connexin-43 in rat spinal cord: localization in astrocytes and identification of heterotypic astro-oligodendrocytic gap junctions. Neuroscience 1997;76:931-945.
33. Zhu X, Conklin D, Eisenach JC: Cyclooxygenase-1 in the spinal cord plays an important role in postoperative pain. Pain 2003;104:15-23.
34. Zhu X, Eisenach JC: Cyclooxygenase-1 in the spinal cord is altered after peripheral nerve injury. Anesthesiology 2003;99:1175-1179.
35. Fonnum F, Johnsen A, Hassel B: Use of fluorocitrate and fluoroacetate in the study of brain metabolism. Glia 1997;21:106-113.
36. Paulsen RE, Contestabile A, Villani L, Fonnum F: An in vivo model for studying function of brain tissue temporarily devoid of glial cell metabolism: the use of fluorocitrate. J Neurochem 1987;48:1377-1385.
37. Milligan ED, Twining C, Chacur M, Biedenkapp J, O'Connor K, Poole S, Tracey K, Martin D, Maier SF, Watkins LR: Spinal glia and proinflammatory cytokines mediate mirror-image neuropathic pain in rats. J Neurosci 2003;23:1026-1040.
38. Milligan ED, O'Connor KA, Nguyen KT, Armstrong CB, Twining C, Gaykema RP, Holguin A, Martin D, Maier SF, Watkins LR: Intrathecal HIV-1 envelope glycoprotein gp120 induces enhanced pain states mediated by spinal cord proinflammatory cytokines. J Neurosci 2001;21:2808-2819.
39. Milligan ED, Mehmert KK, Hinde JL, Harvey LO, Martin D, Tracey KJ, Maier SF, Watkins LR: Thermal hyperalgesia and mechanical allodynia produced by intrathecal administration of the human immunodeficiency virus-1 (HIV-1) envelope glycoprotein, gp120. Brain Res 2000;861:105-116.
40. Meller ST, Dykstra C, Grzybycki D, Murphy S, Gebhart GF: The possible role of glia in nociceptive processing and hyperalgesia in the spinal cord of the rat. Neuropharmacology 1994;33:1471-1478.
41. Tikka TM, Koistinaho JE: Minocycline provides neuroprotection against N-methyl-D-aspartate neurotoxicity by inhibiting microglia. J Immunol 2001;166:7527-7533.
42. Tikka T, Fiebich BL, Goldsteins G, Keinanen R, Koistinaho J: Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia. J Neurosci 2001;21:2580-2588.
43. Aronson AL: Pharmacotherapeutics of the newer tetracyclines. J Am Vet Med Assoc 1980;176:1061-1068.
44. Golub LM, Ramamurthy NS, McNamara TF, Greenwald RA, Rifkin BR: Tetracyclines inhibit connective tissue breakdown: new therapeutic implications for an old family of drugs. Crit Rev Oral Biol Med 1991;2:297-321.
45. Gabler WL, Creamer HR: Suppression of human neutrophil functions by tetracyclines. J Periodontal Res 1991;26:52-58.
46. Gabler WL, Smith J, Tsukuda NL: Comparison of doxycycline and a chemically modified tetracycline inhibition of leukocyte functions. Res Commun Chem Pathol Pharmacol 1992;78:151-160.
47. Amin AR, Attur MG, Thakker GD, Patel PD, Vyas PR, Patel RN, Patel IR, Abramson SB: A novel mechanism of action of tetracyclines: effects on nitric oxide synthases. Proc Natl Acad Sci USA 1996;93:14014-14019.
48. Amin AR, Patel RN, Thakker GD, Lowenstein CJ, Attur MG, Abramson SB: Post-transcriptional regulation of inducible nitric oxide synthase mRNA in murine macrophages by doxycycline and chemically modified tetracyclines. FEBS Lett 1997;410:259-264.
49. Whiteman M, Halliwell B: Prevention of peroxynitrite-dependent tyrosine nitration and inactivation of alpha1-antiproteinase by antibiotics. Free Radic Res 1997;26:49-56.
50. O'Dell JR, Blakely KW, Mallek JA, Eckhoff PJ, Leff RD, Wees SJ, Sems KM, Fernandez AM, Palmer WR, Klassen LW, Paulsen GA, Haire CE, Moore GF: Treatment of early seropositive rheumatoid arthritis: a two-year, double-blind comparison of minocycline and hydroxychloroquine. Arthritis Rheum 2001;44:2235-2241.
51. Kloppenburg M, Breedveld FC, Terwiel JP, Mallee C, Dijkmans BA: Minocycline in active rheumatoid arthritis: a double-blind, placebo-controlled trial. Arthritis Rheum 1994;37:629-636.
52. Raghavendra V, Tanga F, DeLeo JA: Inhibition of microglial activation attenuates the development but not existing hypersensitivity in a rat model of neuropathy. J Pharmacol Exp Ther 2003;306:624-630.
53. Ledeboer A, Sloane E, Chacur M, Milligan ED, Maier SF, Watkins LR: Selective inhibition of spinal cord microglial activation attenuates mechanical allodynia in rat models of pathological pain. Proc Soc Neurosci 2003;29:in press.
54. Wolf G, Yirmiya R, Goshen I, Iverfeldt K, Holmlund L, Takeda K, Shavit Y: Impairment of interleukin-1 (IL-1) signaling reduces basal pain sensitivity in mice: genetic, pharmacological and developmental aspects. Pain 2003;104:471-480.
55. Fedoroff S: Development of microglia; in Kettenmann H, Ransom BR (eds): Neuroglia. New York, Oxford University Press, 1995, pp 162-181.
56. Tsuda M, Shigemoto-Mogami Y, Koizumi S, Mizokoshi A, Kohsaka S, Salter MW, Inoue K: P2X4 receptors induced in spinal microglia gate tactile allodynia after nerve injury. Nature 2003;424:778-783.
57. Janeway CA, Travers P, Walport M, Shlomchik M: Immunobiology, ed 5. Garland Publishing, New York, 2001.
58. Mauviel A: Cytokine regulation of metalloproteinase gene expression. J Cell Biochem 1993;53:288-295.
59. Gallis B, Prickett KS, Jackson J, Slack J, Schooley K, Sims JE, Dower SK: IL-1 induces rapid phosphorylation of the IL-1 receptor. J Immunol 1989;143:3235-3240.
60. Dinarello CA: Interleukin-1. Cytokine Growth Factor Rev 1997;8:253-265.
61. Dinarello CA: Proinflammatory cytokines. Chest 2000;118:503-508.
62. Arruda JL, Colburn RW, Rickman AJ, Rutkowski MD, DeLeo JA: Increase of interleukin-6 mRNA in the spinal cord following peripheral nerve injury in the rat: potential role of IL-6 in neuropathic pain. Brain Res Mol Brain Res 1998;62:228-235.
63. Winkelstein BA, Rutkowski MD, Weinstein JN, DeLeo JA: Quantification of neural tissue injury in a rat radiculopathy model: comparison of local deformation, behavioral outcomes, and spinal cytokine mRNA for two surgeons. J Neurosci Methods 2001;111:49-57.
64. Winkelstein BA, Rutkowski MD, Sweitzer SM, Pahl JL, DeLeo JA: Nerve injury proximal or distal to the DRG induces similar spinal glial activation and selective cytokine expression but differential behavioral responses to pharmacologic treatment. J Comp Neurol 2001;439:127-139.
65. Holguin A, O'Connor K, Hansen MK, Milligan ED, Cheepsunthorn P, Braymann C, Cochran K, Biedenkapp J, Martin D, Maier SF, Watkins LR: HIV-1 gp120-induced spinal proinflammatory cytokine production and low threshold mechanical allodynia are mediated by nitric oxide. Brain Behav Immun 2002;16:191.
66. Winkelstein BA, DeLeo JA: Nerve root injury severity differentially modulates spinal glial activation in a rat lumbar radiculopathy model: considerations for persistent pain. Brain Res 2002;956:294-301.
67. DeLeo JA, Colburn RW, Nichols M, Malhotra A: Interleukin-6-mediated hyperalgesia/allodynia and increased spinal IL-6 expression in a rat mononeuropathy model. J Interferon Cytokine Res 1996;16:695-700.
68. Hashizume H, DeLeo JA: Colburn RW, Weinstein JN: Spinal glial activation and cytokine expression after lumbar root injury in the rat. Spine 2000;25:1206-1217.
69. DeLeo JA, Colburn RW, Rickman AJ: Cytokine and growth factor immunohistochemical spinal profiles in two animal models of mononeuropathy. Brain Res 1997;759:50-57.
70. Sweitzer SM, Colburn RW, Rutkowski M, DeLeo JA: Acute peripheral inflammation induces moderate glial activation and spinal IL-1beta expression that correlates with pain behavior in the rat. Brain Res 1999;829:209-221.
71. Falchi M, Ferrara F, Gharib CB: Dib, Hyperalgesic effect of intrathecally administered interleukin-1 in rats. Drugs Exp Clin Res 2001;27:97-101.
72. Reeve AJ, Patel S, Fox A, Walker K, Urban L: Intrathecally administered endotoxin or cytokines produce allodynia, hyperalgesia and changes in spinal cord neuronal responses to nociceptive stimuli in the rat. Eur J Pain 2000;4:247-257.
73. Oka T, Hori T: Brain cytokines and pain; in Watkins LR, Maier SF (eds): Cytokines and Pain. Basel, Birkhäuser, 1999, pp 183-204.
74. Sweitzer S, Martin D, DeLeo JA: Intrathecal interleukin-1 receptor antagonist in combination with soluble tumor necrosis factor receptor exhibits an anti-allodynic action in a rat model of neuropathic pain. Neuroscience 2001;103:529-539.
75. Laughlin TM, Bethea JR, Yezierski RP, Wilcox GL: Cytokine involvement in dynorphin-induced allodynia. Pain 2000;84:159-167.
76. Sloane EM, Langer SE, Milligan ED, Wieseler-Frank J, Mahoney J, Levkoff L, Cruz P, Flotte TR, Leinwant L, Maier SF, Watkins LR: Chronic constriction injury induced pathological pain states are controlled long term via intrathecal administration of a non-viral vector (NVV) encoding the anti-inflammatory cytokine interleukin-10 (IL-10). Proc Am Pain Soc, 2004.
77. Arruda JL, Sweitzer S, Rutkowski MD, DeLeo JA: Intrathecal anti-IL-6 antibody and IgG attenuates peripheral nerve injury-induced mechanical allodynia in the rat: possible immune modulation in neuropathic pain. Brain Res 2000;879:216-225.
78. Watkins LR, Maier SF: Glia: a novel drug discovery target for clinical pain. Nature Rev Drug Discovery 2003;2:973-985.
79. Hornfeldt CS, Larson AA: Seizures induced by fluoroacetic acid and fluorocitric acid may involve chelation of divalent cations in the spinal cord. Eur J Pharmacol 1990;179:307-313.
80. Sweitzer SM, Schubert P, DeLeo JA: Propentofylline, a glial modulating agent, exhibits antiallodynic properties in a rat model of neuropathic pain. J Pharmacol Exp Ther 2001;297:1210-1217.
81. Schafers M, Svensson CI, Sommer C, Sorkin LS: Tumor necrosis factor-alpha induces mechanical allodynia after spinal nerve ligation by activation of p38 MAPK in primary sensory neurons. J Neurosci 2003;23:2517-2521.
82. Jin SX, Zhuang ZY, Woolf CJ, Ji RR: p38 mitogen-activated protein kinase is activated after a spinal nerve ligation in spinal cord microglia and dorsal root ganglion neurons and contributes to the generation of neuropathic pain. J Neurosci 2003;23:4017-4022.
83. Kim SY, Bae JC, Kim JY, Lee HL, Lee KM, Kim DS, Cho HJ: Activation of p38 MAP kinase in the rat dorsal root ganglia and spinal cord following peripheral inflammation and nerve injury. Neuroreport 2002;13:2483-2486.
84. Svensson CI, Marsala M, Westerlund A, Calcutt NA, Campana WM, Freshwater JD, Catalano R, Feng Y, Protter AA, Scott B, Yaksh TL: Activation of p38 mitogen-activated protein kinase in spinal microglia is a critical link in inflammation-induced spinal pain processing J Neurochem 2003;86:1534-1544.
85. Svensson CI, Hua XY, Protter AA, Powell HC, Yaksh TL: Spinal p38 MAP kinase is necessary for NMDA-induced spinal PGE(2) release and thermal hyperalgesia. Neuroreport 2003;14:1153-1157.
86. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A: Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001;19:683-765.
87. Milligan ED, Langer SE, Sloane E, Chacur M, Wieseler-Frank J, Frank M, Flotte TR, Cruz P, Leinwand L, Maier SF, Watkins LR: Inflammatory and chronic constriction injury-induced pain states are controlled by spinal delivery of viral and non-viral vectors encoding the anti-inflammatory gene, interleukin-10 (IL10). Proc Soc Neurosci, 2003, p 29.
88. Ledeboer A, Wierinckx A, Bol JG, Floris S, Renardel de Lavalette C, De Vries HE, van den Berg TK, Dijkstra CD, Tilders FJ, van dam AM: Regional and temporal expression patterns of interleukin-10, interleukin-10 receptor and adhesion molecules in the rat spinal cord during chronic relapsing EAE. J Neuroimmunol 2003;136:94-103.
89. Milligan, ED, Langer SE, Sloane E, Wieseler-Frank J, Frank M, Levkoff L, Mahoney J, Chavez R, Forsayeth J, Cruz P, Flotte TR, Leinwand L, Maier SF, Watkins LR: Gene therapy using naked plasmid DNA coding the anti-inflammatory gene, interleukin-10 (IL10): repeated injections lead to long-term pain control in chronic constriction injury (CCI) rats. Proc Am Pain Soc, 2004.